12:00 AM
Oct 04, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Endostatin: Began Phase I testing

EntreMed Inc. (ENMD), Rockville, Md.
Product: Endostatin
Business: Cancer
Therapeutic category: Angiogenesis
Target: Tumor blood vessels
Description: Recombinant human endostatin protein fragment...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >